Lupin recalls 42 lots of antibiotic after contaminate found in vials

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/westend61)
(Image: Getty/westend61)

Related tags: Recall, Fda, Injection, Antibiotics, Inspection

Lupin Pharmaceuticals voluntarily recalling lots of Ceftriaxone for Injection after rubber flecks were found in vials.

The recall comes after Ceftriaxone for injection products have been found to contain visual grey particulate matter in reconstituted vials.

The five lots recalled contained Ceftriaxone for Injection, 250mg, 10 lots of Ceftriaxone for Injection, 500mg, 24 lots of Ceftriaxone for Injection, 1g, and three lots of Ceftriaxone for Injection, 2g.

Lupin stated that improper piercing and use of a needle greater than 21 gauge while reconstituting the vial can push rubber flecks into the solution.

No grey flecks were seen prior to the constitution of the vials. The issue was identified after standard visual inspection prior to patient administration.

The product containing rubber particulate matter could cause vein irritation or pulmonary embolic events potentially resulting in permanent impairment of bodily function if injected with the contaminant.

As ceftriaxone can be administered intramuscularly, the use of the product with its contaminant can cause local muscle inflammation and abscesses.

Ceftriaxone is a sterile, semi-synthetic, broad-spectrum cephalosporin antibiotic used to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone sodium, and other antibacterial drugs.

Related news

Show more

Related products

Understanding the hidden value of quality

Understanding the hidden value of quality

Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | Technical / White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Related suppliers

Follow us

Products

View more

Webinars